Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Procedure: Multigated Acquisition Scan; Drug: Osimertinib; Procedure: Radiologic Examination Sponsors: National Cancer Institute (NCI) Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials